Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Empower or fall behind: why true patient engagement is pharma’s competitive edge

By Paul Allen

market access in Japan

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

- PMLiVE

AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

Approximately 6,600 people are diagnosed with liver cancer every year in the UK

- PMLiVE

Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

- PMLiVE

Patient activation – not just a strategy but a necessity

By Becky Paul

- PMLiVE

BMS and Bain Capital launch new company to develop immunology therapies

The newly formed company has in-licensed five investigational immunology drugs from BMS

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

Solving the patient engagement value equation

By Stephen O’Farrell

Biogen Idec building

Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

- PMLiVE

FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata

Approximately 700,000 people in the US currently have some form of the autoimmune disease

- PMLiVE

The power of representation, innovation and trust in rare disease clinical trials

By Carol Pitcher-Towner

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links